Redhill Biophrma ADR (RDHL) 10.58 $RDHL RedHill

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 5:17 PM

Redhill Biophrma ADR (RDHL) 10.58 $RDHL

RedHill Biopharma to Present at the 2016 BIO International Convention
GlobeNewswire - Tue May 31, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Adi Frish, RedHill's Senior VP Business Development & Licensing, will present a corporate overview at the 2016 BIO International Convention, on Tuesday, June 7, 2016, at 11:45 am PDT, at the Moscone Center in San Francisco, CA.
RDHL: 10.58 (-0.20)

RedHill Biopharma to Present at Jefferies 2016 Healthcare Conference
GlobeNewswire - Mon May 30, 8:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases and cancer, today announced that Mr. Gilead Raday, RedHill's Chief Operating Officer, will present a corporate overview at the Jefferies 2016 Healthcare Conference, on Wednesday, June 8, 2016, at 10:00 am EDT, in New York, NY.
RDHL: 10.58 (-0.20)

RedHill Biopharma Announces National Cancer Institute Grant Supporting YELIVA(TM) Phase II Hepatocellular Carcinoma Study
Globe Newswire - Wed May 04, 7:22AM CDT
- The $1.8 million U.S. National Cancer Institute (NCI) grant, awarded to the Medical University of South Carolina (MUSC), is intended to support a research program covering a variety of solid tumor cancers, including a Phase II study with YELIVA(TM) (ABC294640) for the treatment of advanced hepatocellular carcinoma, planned to be initiated in Q3/2016 at MUSC and collaborating institutions
RDHL: 10.58 (-0.20)

RedHill Biopharma to Present at BioNetwork East 2016 Partnering Summit
GlobeNewswire - Mon Apr 25, 7:01AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will present a corporate overview at the BioNetwork East 2016 Partnering Summit, on Monday, May 2, 2016, at 9:20 am EDT, at the Reunion Resort, Orlando, FL.
RDHL: 10.58 (-0.20)

RedHill Biopharma Reports 2016 First Quarter Financial Results
GlobeNewswire - Wed Apr 20, 6:45AM CDT
-- RedHill maintains a strong and debt-free balance sheet with approximately $53 million in cash at the end of the first quarter, allowing the Company to continue to diligently execute its strategic and operational plans, including its three ongoing Phase III gastrointestinal disease programs in the U.S.
RDHL: 10.58 (-0.20)

RedHill Biopharma Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection
Globe Newswire - Mon Apr 18, 7:00AM CDT
- The FDA has confirmed, subject to final minutes of the meeting, the planned two-arm, randomized, double-blind, active comparator design of the confirmatory Phase III study with RHB-105 for the treatment of H. pylori infection, expected to be initiated in the second half of 2016
RDHL: 10.58 (-0.20)

RedHill Biopharma to Host First Quarter 2016 Financial Results Conference Call on April 20, 2016
GlobeNewswire - Wed Apr 13, 7:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

, a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it will report its financial results for the first quarter of 2016 on Wednesday, April 20, 2016.
RDHL: 10.58 (-0.20)

RedHill Biopharma Initiates Phase II Study of BEKINDA(TM) for Irritable Bowel Syndrome
Globe Newswire - Mon Apr 11, 8:00AM CDT
- The randomized, double-blind, 2-arm parallel group Phase II study of BEKINDA(TM) 12 mg is expected to enroll 120 patients suffering from diarrhea-predominant irritable bowel syndrome (IBS-D) in 12 clinical sites in the U.S.
RDHL: 10.58 (-0.20)

RedHill Biopharma Announces Interim Results from Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis
Globe Newswire - Thu Mar 31, 7:03AM CDT
- The ongoing CEASE-MS Phase IIa proof-of-concept (PoC), single-arm, open-label study was designed with a series of exploratory endpoints to evaluate the safety and potential efficacy of fixed oral dose RHB-104 as add-on therapy to interferon beta-1a in 18 patients treated for relapsing-remitting multiple sclerosis (RRMS)
RDHL: 10.58 (-0.20)

IntelGenx and RedHill Biopharma Announce RIZAPORT(TM) Commercialization Term Sheet With Grupo Juste for Spain and Additional Potential Territories
Marketwired - Tue Mar 29, 6:01AM CDT
IntelGenx Corp. (TSX VENTURE: IGX)(OTCQX: IGXT) and RedHill Biopharma Ltd. (NASDAQ: RDHL)(TASE: RDHL) today announced the binding term sheet agreement with Grupo Juste S.A.Q.F for the commercialization of RIZAPORT(TM), a unique oral thin film for the treatment of acute migraines in the country of Spain. The definitive agreement plans to be signed within 60 days of the execution of the binding term sheet. Financial terms of the agreement were not disclosed.
RDHL: 10.58 (-0.20), IGX.VN: 0.690 (-0.020)

RedHill Biopharma and IntelGenx Announce RIZAPORT(TM) Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories
GlobeNewswire - Tue Mar 29, 6:00AM CDT
-- RedHill and its co-development partner, IntelGenx Corp., have entered into a binding term sheet with Grupo JUSTE granting an exclusive license to commercialize their acute migraine drug RIZAPORTin Spain, and a right of first refusal for additional territories
RDHL: 10.58 (-0.20), IGX.VN: 0.690 (-0.020)

RedHill Biopharma to Present at Bio-Europe Spring 2016 Conference
GlobeNewswire - Mon Mar 28, 6:00AM CDT
RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) ("RedHill" or the "Company"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hitachi Vantara's Strategy for AI Data Infrastructure

Building AI-Ready Infrastructure with Hitachi Vantara Here's the scoop, folks: Hitachi Vantara has tossed a new hat in the ring by boosting its Virtual Storage Platform One (VSP One) with fresh, AI-friendly capabilities. This isn't just some fiddle to stay in the tech race; they're laying down the tracks for how we park big AI in enterprise garages without blowing a fuse....

Water Wings Swim School Splashes into Billings

Billings Dives into the Swim School Scene Well, folks, Billings is about to get its feet wet with something new and well-needed in the local scene. Come November 21, Montana will welcome its first dedicated swim school as Water Wings opens shop right here in Billings at 2618 King Ave W. This ain't just run-of-the-mill comic relief on disaster-preparedness. We're talking...

Alogent's Unify Snags Award for Innovation and Impact

Innovation That Captures Attention Alogent sure did grab the spotlight with their Unify platform walking away with a Credit Union Times Luminaries Award. The name of the game here is deposit processing innovation—the kind of buzz that turns heads in the banking world. This recognition isn't just another plaque for the lobby; it's a testament to a significant stamp on...

Otus Earns Top Spot in Education AI at Innovation Awards

Acknowledging AI's Growing Role in Education Times are changing, and the classroom ain't what it used to be. Enter Otus, a platform that's breaking the mold by bringing artificial intelligence smack dab into K-12 education. They've bagged the 2026 SmartBrief Innovation Award in AI within the Education category. Clocking in at serving nearly 100 school districts, it's...

China-Kenya Trade: Avocado Diplomacy in Action

Avocado: A Trade Symbol with a Pit of Potential Who'd have thought a simple avocado could become such a heavyweight in the international trade arena? But here we are, with Kenyan avocados making a splash on the grand stage at the ninth China International Import Expo in Shanghai. Thanks to zero-tariff treatment, Kenya's prized green exports are rolling into China easier...

Caracal's Bold Branding Refresh Fuels Business Growth

A New Chapter for Caracal You ever see a company pulling off a major facelift like it's no big deal? That's exactly how Caracal Products & Services is strutting down the runway. Dubbed a leader in health care solutions, recycling, and spitting out a mix of products across the spectrum, Caracal's hitting the reset button on their brand identities. It's like watching a...

Ladera Resort Snags Prestigious Design Honor in 2027

Recognition for a Unique Architectural Gem What's embedded in the heartbeat of Ladera Resort in St. Lucia? A crazy blend of stunning architecture right smack between the Pitons that makes it like nowhere else on Earth. And guess what? Ladera just snagged the Best Design award for 2027 at the Condé Nast Johansens Awards for Excellence. Winning this honor isn’t about...

Cannabis Campaign Sheds Light on Prohibition's Cost

Behind the Green Curtain of Cannabis Legalization These days, walking into a store to buy cannabis is as casual as picking up milk for many Americans. Legalization has turned a once-taboo substance into a legal indulgence. But before you light up and float away, let's take a moment to dig into the murk that's left behind, folks still clawing through the shadows of a...

Lawyers Juggle AI's Promise and Perils in 2026

AI's Growing Pains in the Legal Arena Looks like the legal eagles are getting a run for their money with AI entering the courtroom. Bloomberg Law's 2026 AI in Practice report dives deep into this legal labyrinth. You got attorneys leaning on AI to keep the gears turning, but they're also clutching their pearls over potential pitfalls. Trust Issues: Humans vs. Machines The...

Teciem Boosts Board with Banking Tech Leader

By Addison Perry Updated Nov 11, 2026 Category News Views 107

A Pinch of Pragmatism in Teciem's Boardroom Teciem's board just got a shot of reality with the appointment of Alla Whitston from MUFG Americas. Now, how often can one say a board director actually knows what it’s like on the other side of the vendor relationship? Not often, my friends. But here you’ve got Whitston, who's seen all the tech tribulations banks face from...